The Latest In Transhumanist Medicine: The SynCardia Temporary Total Artificial Heart

(3BL Media/Justmeans) – We are a society focused on improving human health. One of the most important goals is to have a healthy heart, especially as heart disease is the number one killer in America. It claims nearly 800,000 lives every year, making it the cause of roughly one in three deaths. Globally, an estimated 17.5 million people died from heart disease in 2012, representing 31 percent of all global deaths. Now, radical new medical technology may soon change that. SynCardia Systems, Inc. has recently earned a 2015 Gold Edison Award for the clinical study into the effectiveness of the SynCardia temporary Total Artificial Heart, powered by the Freedom® portable driver. This award recognises the best in innovative product and service development.

SynCardia Systems, Inc. is the manufacturer of the world's first and only Food and Drug Administration (FDA)- Health Canada- and CE-approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure, where both ventricles can no longer pump enough blood for a person to survive. The 13.5-pound Freedom® portable driver allows clinically stable patients to be discharged from the hospital to resume their lives at home and in their communities. Patients can recover and gain strength as they wait for their matching donor hearts. The discharge helps Freedom® portable driver patients to get in better shape for their heart transplants while getting back to their daily lives.

Now, SynCardia is to embark on a FDA-approved Investigational Device Exemption study that will allow 19 patients in the primary arm of the study and up to 19 patients in the secondary arm, those who do not meet study criteria under the current approved protocol. This study will hopefully provide patients with a second chance at life. The SynCardia Heart is already FDA-approved as a bridge to a donor heart transplant and has been implanted more than 1,475 times. It’s is the only commercially available Total Artificial Heart in the U.S., European Union and Canada.

More than 1,475 implants of the SynCardia Total Artificial Heart account for over 480 patient years of life on the device; since 2012 more than 500 SynCardia Hearts have been implanted. The youngest patient to receive a SynCardia Heart was just nine years old, the oldest was 80; the longest a patient has lived with this heart was nearly four years, before receiving a donor heart transplant. Replacing the human heart with a robotic version is on the rise around the world. However, nearly all operations currently carried out are only a temporary bridge to buy precious time until a biological heart transplant can be made.

Transplants of biological hearts, while often successful, are very difficult to come by, due to a shortage of suitable organs. At any given time, over 100,000 people around the world are waiting for a heart. There simply are not enough healthy hearts available for the thousands who need them, which is why the SynCardia Heart, the latest in transhumanist medicine is giving people hope and helping to buy precious time until a biological heart transplant can be performed.  

Photo Credit: SynCardia Systems, Inc